UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons

The Journal of neuroscience, 2012-03, Vol.32 (13), p.4610-4622

2012

Volltextzugriff (PDF)

Qualitative Exploration of the Visual Function Impairments and Health-Related Quality of Life Impacts of Amblyopia in Adult and Pediatric Populations

Ophthalmology and therapy, 2023-10, Vol.12 (5), p.2505-2528

2023

Volltextzugriff (PDF)

The Amblyopia Quality of Life (AmbQoL): Development and Content Validation of a Novel Health-Related Quality of Life Instrument for Use in Adult and Pediatric Amblyopia Populations

Ophthalmology and therapy, 2023-04, Vol.12 (2), p.1281-1313

2023

Volltextzugriff (PDF)

Integrin clustering as a result of local membrane deformations and local signaling feedbacks

Physica A, 2014-08, Vol.408, p.198-211

2014

Volltextzugriff (PDF)

A Social Media Listening Study to Understand the Unmet Needs and Quality of Life in Adult and Pediatric Amblyopia Patients

Ophthalmology and therapy, 2022-12, Vol.11 (6), p.2183-2196

2022

Volltextzugriff (PDF)

Semiparametric estimation of the cure fraction in population‐based cancer survival analysis

Statistics in medicine, 2020-11, Vol.39 (26), p.3787-3805

2020

Volltextzugriff (PDF)

Mixture Cure Models in Oncology: A Tutorial and Practical Guidance

PharmacoEconomics - open, 2021-06, Vol.5 (2), p.143-155

2021

Volltextzugriff (PDF)

Network-of-queues approach to B-cell-receptor affinity discrimination

Physical review. E, Statistical, nonlinear, and soft matter physics, 2012-06, Vol.85 (6 Pt 1), p.061926-061926, Article 061926

2012

Volltextzugriff (PDF)

Enhanced cellular sensitivity from partitioning the integrin receptors into multiple clusters

Physical review. E, Statistical, nonlinear, and soft matter physics, 2013-01, Vol.87 (1), p.012701-012701, Article 012701

2013

Volltextzugriff (PDF)

Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force

Value in health, 2022-07, Vol.25 (7), p.1063-1080

2022

Volltextzugriff (PDF)

Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood, 2020-11, Vol.136 (Supplement 1), p.41-42

2020

Volltextzugriff (PDF)

Cost-Effectiveness of Polatuzumab Vedotin Plus Bendamustine-Rituximab for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States

Blood, 2020-11, Vol.136 (Supplement 1), p.3-3

2020

Volltextzugriff (PDF)

Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer

Clinical lung cancer, 2018-09, Vol.19 (5), p.441-449.e4

2018

Volltextzugriff (PDF)

Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France

Journal of medical economics, 2020-05, Vol.23 (5), p.464-473

2020

Volltextzugriff (PDF)

Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis

Diabetes therapy, 2023-07, Vol.14 (7), p.1193-1216

2023

Volltextzugriff (PDF)

Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)

Journal of medical economics, 2019-07, Vol.22 (7), p.625-637

2019

Volltextzugriff (PDF)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma

Journal of managed care & specialty pharmacy, 2021-05, Vol.27 (5), p.615-624

2021

Volltextzugriff (PDF)

IBCL-199: Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S280-S280

2020

Volltextzugriff (PDF)

Consolidated Health Economic Evaluation Reporting Standards for Interventions That Use Artificial Intelligence (CHEERS-AI)

Value in health, 2024-09, Vol.27 (9), p.1196-1205

2024

Volltextzugriff (PDF)

Analyzing and constraining signaling networks: parameter estimation for the user

Methods in molecular biology (Clifton, N.J.), 2012, Vol.880, p.23

2012

Volltextzugriff (PDF)

Abstract PO-58: Obinutuzumab plus chemotherapy is cost effective versus rituximab biosimilars plus chemotherapy for previously untreated follicular lymphoma patients

Blood cancer discovery, 2020-11, Vol.1 (3_Supplement), p.PO-58-PO-58

2020

Volltextzugriff (PDF)

US cost–effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma

Journal of comparative effectiveness research, 2020-10, Vol.9 (14), p.1003-1015

2020

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons

Qualitative Exploration of the Visual Function Impairments and Health-Related Quality of Life Impacts of Amblyopia in Adult and Pediatric Populations

The Amblyopia Quality of Life (AmbQoL): Development and Content Validation of a Novel Health-Related Quality of Life Instrument for Use in Adult and Pediatric Amblyopia Populations

Integrin clustering as a result of local membrane deformations and local signaling feedbacks

A Social Media Listening Study to Understand the Unmet Needs and Quality of Life in Adult and Pediatric Amblyopia Patients

Semiparametric estimation of the cure fraction in population‐based cancer survival analysis

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Mixture Cure Models in Oncology: A Tutorial and Practical Guidance

Network-of-queues approach to B-cell-receptor affinity discrimination

Enhanced cellular sensitivity from partitioning the integrin receptors into multiple clusters

Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force

Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Cost-Effectiveness of Polatuzumab Vedotin Plus Bendamustine-Rituximab for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States

Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer

Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France

Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis

Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma

IBCL-199: Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma

Consolidated Health Economic Evaluation Reporting Standards for Interventions That Use Artificial Intelligence (CHEERS-AI)

Analyzing and constraining signaling networks: parameter estimation for the user

Abstract PO-58: Obinutuzumab plus chemotherapy is cost effective versus rituximab biosimilars plus chemotherapy for previously untreated follicular lymphoma patients

US cost–effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma

Suchergebnisse filtern